ID 113050
Author
Iwamoto, Takayuki Okayama University
Niikura, Naoki Tokai University
Miyoshi, Yuichiro Okayama University
Kochi, Mariko Okayama University
Nogami, Tomohiro Okayama University
Shien, Tadahiko Okayama University
Motoki, Takayuki Okayama University
Taira, Naruto Okayama University
Omori, Masako Okayama University
Tokuda, Yutaka Tokai University
Fujiwara, Toshiyoshi Okayama University
Doihara, Hiroyoshi Okayama University
Gyorffy, Balazs MTA TTK Lendület Cancer Biomarker Research Group|Semmelweis University
Matsuoka, Junji Okayama University
Keywords
short-term hormone therapy
IHC Ki67
genomic marker
breast cancer
Content Type
Journal Article
Description
Background: The purpose of this study was to test whether immunohistochemical (IHC) Ki67 levels after short-term preoperative hormone therapy (post-Ki67) predict similar numbers of patients with favorable prognoses as genomic markers.
Results: Thirty paired cases (60 samples) were enrolled in this study. Post-Ki67 levels were significantly lower than pre-treatment Ki67 levels (P < 0.001). Post-Ki67 predicted more low-risk cases (83.3%, 25/30) than pre-genomic surrogate signature(GSS) (66.7%: 20/30), but the difference in predictive power was not significant (P = 0.233). Proliferation (MKI67, STK15, Survivin, CCNB1, and MYBL2) and estrogen (ER, PGR, BCL2, and SCUBE2) related signatures were significantly downregulated after therapy (P < 0.001 and 0.041, respectively).
Materials and Methods: Core needle biopsy specimens of primary breast cancer were collected at Okayama University Hospital from hormone receptor-positive and human epidermal growth factor 2-negative patients that subsequently received two weeks of neoadjuvant hormone therapy. Paired post-treatment specimens from surgical samples were also collected. IHC Ki67 levels and GSS were compared between pre- and post-hormone treatment samples. Changes of gene expression pattern in short-term hormone therapy were also assessed.
Conclusions: IHC based post-Ki67 levels may have distinct predictive power compared with the naïve IHC Ki67. Future studies with larger cohorts and longer follow-up periods may be needed to validate our results.
Journal Title
Oncotarget
ISSN
19492553
Publisher
Impact Journals, LLC
Volume
8
Issue
16
Start Page
26122
End Page
26128
Published Date
2017-02-16
Rights
Copyright: Iwamoto et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY)(https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Institute of Advanced Medical Sciences